234 related articles for article (PubMed ID: 26872388)
21. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
White KL; Kulkarni R; McColl DJ; Rhee MS; Szwarcberg J; Cheng AK; Miller MD
Antivir Ther; 2015; 20(3):317-27. PubMed ID: 25321623
[TBL] [Abstract][Full Text] [Related]
22. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance.
Bruce RD; Winkle P; Custodio JM; Wei X; Rhee MS; Kearney BP; Ramanathan S; Friedland GH
Antimicrob Agents Chemother; 2013 Dec; 57(12):6154-7. PubMed ID: 24080665
[TBL] [Abstract][Full Text] [Related]
23. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
Penchala SD; Fawcett S; Else L; Egan D; Amara A; Elliot E; Challenger E; Back D; Boffito M; Khoo S
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():174-80. PubMed ID: 27290668
[TBL] [Abstract][Full Text] [Related]
24. Effects of Milk or Apple Juice Ingestion on the Pharmacokinetics of Elvitegravir and Cobicistat in Healthy Japanese Male Volunteers: A Randomized, Single-Dose, Three-Way Crossover Study.
Yonemura T; Okada N; Sagane K; Okamiya K; Ozaki H; Iida T; Yamada H; Yagura H
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):737-743. PubMed ID: 29364579
[TBL] [Abstract][Full Text] [Related]
25. Elvitegravir for the treatment of HIV.
Unger NR; Worley MV; Kisgen JJ; Sherman EM; Childs-Kean LM
Expert Opin Pharmacother; 2016 Dec; 17(17):2359-2370. PubMed ID: 27767362
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents.
Ramanathan S; Mathias A; Wei X; Shen G; Koziara J; Cheng A; Kearney BP
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):45-50. PubMed ID: 23774876
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
28. Effect of ethanol on spectral binding, inhibition, and activity of CYP3A4 with an antiretroviral drug nelfinavir.
Kumar S; Earla R; Jin M; Mitra AK; Kumar A
Biochem Biophys Res Commun; 2010 Nov; 402(1):163-7. PubMed ID: 20937259
[TBL] [Abstract][Full Text] [Related]
29. Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.
Andreatta K; Kulkarni R; Abram ME; Nguyen T; Cao H; Miller MD; White KL
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):519-26. PubMed ID: 25559592
[TBL] [Abstract][Full Text] [Related]
30. Enhanced methamphetamine metabolism in rhesus macaque as compared with human: an analysis using a novel method of liquid chromatography with tandem mass spectrometry, kinetic study, and substrate docking.
Earla R; Kumar S; Wang L; Bosinger S; Li J; Shah A; Gangwani M; Nookala A; Liu X; Cao L; Jackson A; Silverstein PS; Fox HS; Li W; Kumar A
Drug Metab Dispos; 2014 Dec; 42(12):2097-108. PubMed ID: 25301936
[TBL] [Abstract][Full Text] [Related]
31. Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4.
Nookala AR; Li J; Ande A; Wang L; Vaidya NK; Li W; Kumar S; Kumar A
PLoS One; 2016; 11(1):e0146529. PubMed ID: 26741368
[TBL] [Abstract][Full Text] [Related]
32. Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells.
Wu JJ; Ge GB; He YQ; Wang P; Dai ZR; Ning J; Hu LH; Yang L
AAPS J; 2016 Jan; 18(1):134-45. PubMed ID: 26361765
[TBL] [Abstract][Full Text] [Related]
33. Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.
Nguyen T; McNicholl I; Custodio JM; Szwarcberg J; Piontkowsky D
AIDS Rev; 2016; 18(2):101-11. PubMed ID: 27196356
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
Rockstroh JK; DeJesus E; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Plummer A; Abram M; Cheng AK; Fordyce MW; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 Apr; 62(5):483-6. PubMed ID: 23337366
[TBL] [Abstract][Full Text] [Related]
35. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
36. An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.
Youdim KA; Lyons R; Payne L; Jones BC; Saunders K
J Pharm Biomed Anal; 2008 Sep; 48(1):92-9. PubMed ID: 18584988
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
Ramanathan S; Mathias AA; German P; Kearney BP
Clin Pharmacokinet; 2011 Apr; 50(4):229-44. PubMed ID: 21348537
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
German P; Warren D; West S; Hui J; Kearney BP
J Acquir Immune Defic Syndr; 2010 Nov; 55(3):323-9. PubMed ID: 20683270
[TBL] [Abstract][Full Text] [Related]
39. Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
Di Biagio A; Prinapori R; Taramasso L; Gustinetti G; Sticchi L; Bruzzone B; Viscoli C
Recent Pat Antiinfect Drug Discov; 2014; 9(1):41-51. PubMed ID: 25030944
[TBL] [Abstract][Full Text] [Related]
40. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
Cid-Silva P; Llibre JM; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Pernas-Souto B; Martín-Herranz I; Castro-Iglesias Á; Poveda E
Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):442-446. PubMed ID: 28627771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
